Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Stocks Pressured by US and European Standoff Over Greenland

View original at nasdaq.com
Stocks Pressured by US and European Standoff Over Greenland The S&P 500 Index ($SPX) (SPY) today is down -1.23%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -1.07%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.36%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rockwell Automation downgraded to perform from outperform

    80% confidence
  • Micron Technology price target raised to $360 from $300

    80% confidence
  • Albemarle upgraded to buy from hold with price target of $200

    80% confidence
  • Concerns about systemic compliance risks and suspicions of financial crimes at AppLovin

    80% confidence
  • NetApp downgraded to underweight from equal weight with price target of $89

    80% confidence
  • 10% tariff on goods from eight European countries starting February 1, rising to 25% in June, unless there's a deal for the purchase of Greenland

    80% confidence
  • Ruled out joining a US-led peace initiative

    80% confidence
  • Brinker International upgraded to overweight from equal weight with price target of $200

    80% confidence
  • Tesla is on track for 70%-80% gross margins

    80% confidence
  • 2026 adjusted EPS forecast of $8.50-$8.70

    80% confidence
  • Intel upgraded to buy from neutral with price target of $65

    80% confidence
  • S&P earnings growth expected to climb by +8.4% in Q4

    80% confidence
  • Will implement temporary sales tax cut on food if she wins a fresh mandate for her new coalition

    80% confidence
  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings expected to increase by +4.6%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com